Oxcarbazepine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Oxcarbazepine: From Partial Epilepsy to Visual Epilepsy
One-Sentence Summary
Oxcarbazepine is an antiseizure medication originally used to treat partial (focal) epilepsy. The TxGNN model predicts it may be effective for visual epilepsy, but there are currently 0 registered clinical trials and only general epilepsy literature (16 publications, mostly reviews and guidelines) supporting this direction. The evidence is indirect, so this is a model-driven hypothesis at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Partial epilepsy; partial motor epilepsy |
| Predicted New Indication | Visual epilepsy |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L4 |
| US Market Status | Cancelled only (no currently valid licenses in the data compiled) |
| Number of NDAs | 11 authorizations in total (1 NDA, 10 ANDAs; all cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Based on the literature, oxcarbazepine is a derivative of carbamazepine. Its active metabolite, the monohydroxy derivative (MHD), is responsible for its clinical efficacy. It is thought to act by blocking voltage-gated sodium channels, which reduces neuronal hyperexcitability and limits the spread of focal discharges.
Visual epilepsy is a focal, visually triggered seizure type. Because oxcarbazepine’s efficacy in focal seizures is well established, sodium channel blockade is a plausible mechanism for seizures triggered by visual stimuli.
However, the retrieved literature consists of general antiseizure medication reviews and guidelines on focal epilepsy. None specifically addresses visually induced or reflex seizures. The prediction therefore rests mainly on the model score and on the drug’s known activity in focal epilepsy.
Other predicted indications follow a similar pattern. Most are rare reflex seizure types (audiogenic, eating, thinking, startle, micturition-induced, orgasm-induced, reading seizures) with scores of about 99.8–99.9%. Restless legs syndrome has case-report-level support, and status epilepticus has a small case-level report plus a safety signal. All have no registered clinical trials.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No publication addresses visual epilepsy directly. The table lists the most relevant general epilepsy publications retrieved.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35380580 | 2022 | Review | JAMA | Review of antiseizure medications for adults with epilepsy |
| 29898971 | 2018 | Guideline | Neurology | AAN/AES guideline update on newer antiepileptic drugs in new-onset epilepsy |
| 33334546 | 2020 | Review | Seizure | Current role of carbamazepine and oxcarbazepine in epilepsy management |
| 39899099 | 2025 | Review | Continuum | Update on antiseizure medications, covering pharmacokinetics, indications and modes of use |
| 35194860 | 2022 | Systematic review/NMA | Addiction | Comparative efficacy of pharmacotherapies for alcohol withdrawal; not specific to visual epilepsy |
| 17560495 | 2007 | Review | Pediatric Neurology | Antiepileptic drugs and visual function; reviews visual adverse effects |
| 11772334 | 2002 | Review | Expert Opin Pharmacother | Oxcarbazepine efficacy in partial seizures; also in trigeminal neuralgia and bipolar disorder |
| 1379159 | 1992 | Review | Drugs | Pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders |
| 35431799 | 2022 | Review | Front Mol Neurosci | Phenotypes, treatment and prognosis in 72 children with SCN2A-related epilepsy |
| 26844734 | 2016 | Review | Continuum | Individual antiepileptic drugs, key pharmacokinetics and use |
US Market Information
All authorizations below are listed as cancelled. Approved indication text was not available in the data compiled.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA021014 | Trileptal (Novartis) | Tablet, film coated | Not available |
| ANDA077794 | Oxcarbazepine (Sun Pharmaceutical) | Tablet, film coated | Not available |
| ANDA211747 | Oxcarbazepine (Zydus Lifesciences) | Tablet | Not available |
| ANDA213369 | Oxcarbazepine (Apotex) | Tablet, extended release | Not available |
| ANDA209652 | Oxcarbazepine (Bionpharma) | Suspension | Not available |
The full set comprises 11 authorizations, including film-coated tablet, extended-release tablet, and suspension forms.
Safety Considerations
Package insert warnings and contraindications were not available in the data compiled. Please refer to the package insert for these.
- Contraindication-related conditions (knowledge graph, not label text): anxiety disorder, neurotic disorder, dysthymic disorder, impaired renal function, inappropriate ADH syndrome (SIADH), and nephrogenic syndrome of inappropriate antidiuresis. These are database associations and should be verified against the label.
- Drug Interactions: 100 interactions were identified. The 20 listed in detail are all Moderate level, including hydrocortisone, dexamethasone, betamethasone, triamcinolone, cholecalciferol, calcifediol, calcitriol, pioglitazone, aprepitant, morphine, omeprazole, clarithromycin, saxagliptin, linagliptin and chlorpropamide.
- Class-related signal: Sodium channel blockers can aggravate some generalized epilepsies. A case report describes oxcarbazepine-induced myoclonic status epilepticus in juvenile myoclonic epilepsy (PMID 23774821).
Conclusion and Next Steps
Decision: Hold
Rationale: The 99.95% TxGNN score is a model prediction only. There are no clinical trials, and the literature is general epilepsy material that does not address visual epilepsy. Package insert safety data are also missing, which blocks safety screening. All US authorizations are currently cancelled.
To proceed, the following is needed:
- FDA package insert warnings and contraindications (blocking data gap)
- Detailed mechanism of action data (MOA)
- Targeted literature search for oxcarbazepine in visually induced or photosensitive seizures, including case series
- Clinical rationale for the diagnostic boundary between visual epilepsy and existing focal epilepsy indications
- Review of the current US marketing status, since all licenses are listed as cancelled
- Consideration of better-supported alternatives from the same prediction list, such as restless legs syndrome (case reports only, so still exploratory)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.